Portal de investigación
Applicability of probabilistic graphical models for early detection of SARS-CoV-2 reactive antibodies after SARS-CoV-2 vaccination in hematological patients
Fecha de publicación:
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Caballero D.
- Martino R.
- Lopez-Corral L.
- Terol M.-J.
- Vazquez L.
- Calabuig M.
- Sanz-Linares G.
- Marin-Jimenez F.
- Alonso C.
- Ferrer E.
- Facal A.
- Pascual M.-J.
- Rodriguez-Fernandez A.
- Olave M.T.
- Cascales-Hernandez A.
- Gago B.
- Hernández-Rivas J.-Á.
- Villalon L.
- Corona M.
- Roldán-Pérez A.
- Ribes-Amoros J.
- González-Santillana C.
- Garcia-Sanz R.
- Navarro D.
- Serrano-López A.J.
- Cedillo Á.
- Soria-Olivas E.
- Sureda A.
- Solano C.
Grupos
Abstract
Prior studies of antibody response after full SARS-CoV-2 vaccination in hematological patients have confirmed lower antibody levels compared to the general population. Serological response in hematological patients varies widely according to the disease type and its status, and the treatment given and its timing with respect to vaccination. Through probabilistic machine learning graphical models, we estimated the conditional probabilities of having detectable anti-SARS-CoV-2 antibodies at 3–6 weeks after SARS-CoV-2 vaccination in a large cohort of patients with several hematological diseases (n= 1166). Most patients received mRNA-based vaccines (97%), mainly Moderna® mRNA-1273 (74%) followed by Pfizer-BioNTech® BNT162b2 (23%). The overall antibody detection rate at 3 to 6 weeks after full vaccination for the entire cohort was 79%. Variables such as type of disease, timing of anti-CD20 monoclonal antibody therapy, age, corticosteroids therapy, vaccine type, disease status, or prior infection with SARS-CoV-2 are among the most relevant conditions influencing SARS-CoV-2-IgG-reactive antibody detection. A lower probability of having detectable antibodies was observed in patients with B-cell non-Hodgkin’s lymphoma treated with anti-CD20 monoclonal antibodies within 6 months before vaccination (29.32%), whereas the highest probability was observed in younger patients with chronic myeloproliferative neoplasms (99.53%). The Moderna® mRNA-1273 compound provided higher probabilities of antibody detection in all scenarios. This study depicts conditional probabilities of having detectable antibodies in the whole cohort and in specific scenarios such as B cell NHL, CLL, MM, and cMPN that may impact humoral responses. These results could be useful to focus on additional preventive and/or monitoring interventions in these highly immunosuppressed hematological patients. © 2022, The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Datos de la publicación
- ISSN/ISSNe:
- 0939-5555, 1432-0584
- Tipo:
- Article
- Páginas:
- 2053-2067
- PubMed:
- 35780254
- Enlace a otro recurso:
- www.scopus.com
- Factor de Impacto:
- 0,994 SCImago ℠
- Cuartil:
- Q1 SCImago ℠
ANNALS OF HEMATOLOGY SPRINGER
Documentos
- No hay documentos
Filiaciones
Keywords
- Antibodies, Monoclonal; Antibodies, Viral; Antineoplastic Agents; BNT162 Vaccine; COVID-19; COVID-19 Vaccines; Early Detection of Cancer; Humans; SARS-CoV-2; Vaccination; elasomeran; immunoglobulin G antibody; monoclonal antibody; SARS-CoV-2 antibody; tozinameran; antineoplastic agent; monoclonal antibody; virus antibody; adult; aged; antibody detection; Article; B cell lymphoma; cohort analysis; coronavirus disease 2019; drug effect; female; follow up; hematologic disease; human; infection prevention; major clinical study; male; multicenter study; nonhodgkin lymphoma; observational study; probability; treatment outcome; treatment planning; vaccination; diagnosis; early cancer diagnosis; prevention and control